Central Nervous System
In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.
Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia,
migraine, insomnia, epilepsy, etc.
A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.
Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more.
Show Less
Read more
Delirium Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Delirium Global Clinical Trials Review, H1, 2013" provides data on the Delirium clinical trial scenario. This report...
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Dyskinesia Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Dyskinesia clinical trial scenario....
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Radiculopathy Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Radiculopathy Global Clinical Trials Review, H1, 2013" provides data on the Radiculopathy clinical trial scenario....
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Anorexia Nervosa Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Anorexia Nervosa Global Clinical Trials Review, H1, 2013" provides data on the Anorexia Nervosa clinical...
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Anesthetic Effect - Pipeline Review, H1 2013
Anesthetic Effect – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Anesthetic Effect - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Memory Impairment - Pipeline Review, H1 2013
Memory Impairment – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Friedreich Ataxia - Pipeline Review, H1 2013
Friedreich Ataxia – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Friedreich Ataxia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Partial Seizure - Pipeline Review, H1 2013
Partial Seizure – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Partial Seizure - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013
Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indication’s...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Psychiatric Disorders - Pipeline Review, H1 2013
Psychiatric Disorders – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Ischemic Stroke - Pipeline Review, H1 2013
Ischemic Stroke – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013" provides data on the Lennox-Gastaut...
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Tardive Dyskinesia Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Tardive Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Tardive Dyskinesia clinical...
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Dyslexia Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Dyslexia Global Clinical Trials Review, H1, 2013" provides data on the Dyslexia clinical trial scenario. This report...
April
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Global Bipolar Disorder Pipeline Capsule - 2013
Fore Pharma’s latest report ‘Global Bipolar Disorder Pipeline Capsule – 2013’ provides up-to-date information on key Research and Development (R&D) activities in the global bipolar disorder market....
April
2013
FROM
EUR 528USD 690GBP 445AUD 734JPY 67,575SEK 4 569CHF 649CAD 717
Mild Cognitive Impairment - Pipeline Review, H1 2013
Mild Cognitive Impairment – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Mild Cognitive Impairment - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Traumatic Brain Injury - Pipeline Review, H1 2013
Traumatic Brain Injury – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Traumatic Brain Injury - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Chronic Pain - Pipeline Review, H1 2013
Chronic Pain – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Chronic Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Alcohol Addiction - Pipeline Review, H1 2013
Alcohol Addiction – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Alcohol Addiction - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Depression - Pipeline Review, H1 2013
Depression – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Depression - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
